BioSpace News Archive

Aesthetic Medical International Holdings Group Limited (the “Company” or Nasdaq: AIH), a leading provider of aesthetic medical services in China, today announced that the Company will host its fourth quarter and fiscal year 2019 earnings conference call on Friday, April 24, 2020 at 8:00 am Eastern Time (5:00 am Pacific Time/ 8:00 pm Beijing Time) to discuss the Company’s financial results for the fourth quarter and fiscal year ended December 31, 2019.

Hutchison China MediTech Limited announces that the U.S. Food and Drug Administration has granted two Fast Track Designations for the development of surufatinib, for the treatment of both advanced and progressive pancreatic neuroendocrine tumors and extra-pancreatic NET in patients who are not amenable for surgery.

The injectable route of administration is quite common for faster delivery of drugs and medication.

The presence of a large number of players renders high fragmentation in the global patient monitoring and ultrasound devices display market, says Transparency Market Research in a new report.

Preserving biological samples against contamination, which can be caused merely via exposure to the environment, is paramount for those operating in the fields of pharmaceuticals, biopharmaceuticals, diagnostic and testing laboratories, and research academies.

Highlight Therapeutics, a clinical-stage biopharmaceutical company developing RNA-based therapies against cancer, announces the appointment of Carlos Paya, MD, PhD, as Executive Chairman with immediate effect.

Mesoblast Limited announced that results using its allogeneic mesenchymal stem cell product candidate remestemcel-L in patients with inflammatory lung disease have been selected for oral presentation at the 2020 International Society of Cell and Gene Therapy annual meeting being held May 28-29, 2020.

Haemonetics Corporation, a global medical technology company focused on delivering innovative hematology solutions to drive better patient outcomes, announced the election of Michael Coyle to its Board of Directors.

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided a business update, and introduced select preliminary unaudited guidance for the first quarter of 2020. “As we and the rest of the world grapple with the humanitarian crisis and economic uncertainties brought on by the ongoing COVID-19 pandemic, we continue to advance toward our goal of making our gammaCore Sapphire™ non-invasive vagus ner

Genetic Technologies Limited has developed a detailed implementation plan to enable a temporary transition of our genetic testing laboratory to a high-throughput COVID-19 testing laboratory, should it be required by Government agencies to assist with demand.